EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study

Alexandra J Borst iD, Whitney Eng, Morgan Griffin, Kiersten W Ricci iD, Elissa Engel, Denise M Adams, Jillian Dayneka, Sally J Cohen-Cutler, Steven M Andreoli, Melinda D Wu, Allison P Wheeler, Kenneth M Heym iD und 12 weitere

Pediatric Blood & Cancer · 2024-03 · 71 (3)

DOI: 10.1002/pbc.30779 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 10.12.2023. Verfasst von Alexandra J Borst und 23 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine at the University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Kasabach-Merritt Syndrome, Vascular Neoplasms, Hemangioendothelioma, Sarcoma, Kaposi. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare vascular tumors in children historically associated with significant morbidity and mortality. This study was conducted to determine first‐line therapy in the absence of available prospective clinical trials.

Methods

Patients from 17 institutions diagnosed with KHE/TA between 2005 and 2020 with more than 6 months of follow‐up were included. Response rates to sirolimus and vincristine were compared at 3 and 6 months. Durability of response and response to other treatment modalities were also evaluated.

Results

Of 159 unique KHE/TA subjects, Kasabach–Merritt phenomenon (KMP) was present in 64 (40.3%), and only two patients were deceased (1.3%). Over 60% ( n = 96) demonstrated treatment response at 3 months, and more than 70% ( n = 114) by 6 months (no significant difference across groups). The vincristine group had higher radiologic response at 3 months compared to sirolimus (72.7% vs. 20%, p = .03), but there were no differences between these groups at 6 months. There were no differences in rates of recurrent or progressive disease between vincristine and sirolimus.

Conclusions

In this large, multicenter cohort of 159 patients with KHE/TA, rates of KMP were consistent with historical literature, but the mortality rate (1.3%) was much lower. Overall treatment response rates were high (>70%), and there was no significant difference in treatment response or durability of disease comparing sirolimus to vincristine. Our results support individualized treatment decision plans depending on clinical scenario and patient/physician preferences. Response criteria and response rates reported here will be useful for guiding future treatment protocols for vascular tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kasabach-Merritt SyndromeVascular NeoplasmsHemangioendotheliomaSarcoma, KaposiHemangiomaSkin NeoplasmsChildHumansVincristineProspective StudiesSirolimus

Stichwörter der Autor:innen

pediatric hematology/oncologyrare tumorsvascular malformations

Substanzen

VincristineSirolimus

Autor:innen und Institutionen

  • Perelman School of Medicine at the University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Harvard Medical School/Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
  • The University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Tulane School of Medicine/Children's Hospital New Orleans, New Orleans, Louisiana, USA.
  • Keck School of Medicine of University of Southern California/Children's Hospital Los Angeles, Los Angeles, California, USA.
  • University of Florida College of Medicine-Jacksonville/Nemours Children's Specialty Care, Jacksonville, Florida, USA.

ORCID-Profile: Alexandra J Borst, Kiersten W Ricci, Kenneth M Heym, Shelley E Crary, Taizo A Nakano, Bhuvana A Setty, Thomas W McLean, Michael R Jeng

Förderung

  • NCI NIH HHS

Zitieren

APA

Borst, A. J., Eng, W., Griffin, M., Ricci, K. W., Engel, E., Adams, D. M., Dayneka, J., Cohen-Cutler, S. J., Andreoli, S. M., Wu, M. D., Wheeler, A. P., Heym, K. M., Crary, S. E., Nakano, T. A., Schulte, R. R., Setty, B. A., McLean, T. W., Pahl, K. S., Intzes, S., …, & Jeng, M. R. (2024). Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study. Pediatric Blood & Cancer, 71(3). https://doi.org/10.1002/pbc.30779

Vancouver

Borst AJ, Eng W, Griffin M, Ricci KW, Engel E, Adams DM, et al. Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study. Pediatric Blood & Cancer. 2024;71(3). doi:10.1002/pbc.30779

BibTeX
@article{Borst2024,
  author = {Borst, Alexandra J and Eng, Whitney and Griffin, Morgan and Ricci, Kiersten W and Engel, Elissa and Adams, Denise M and Dayneka, Jillian and Cohen-Cutler, Sally J and Andreoli, Steven M and Wu, Melinda D and Wheeler, Allison P and Heym, Kenneth M and Crary, Shelley E and Nakano, Taizo A and Schulte, Rachael R and Setty, Bhuvana A and McLean, Thomas W and Pahl, Kristy S and Intzes, Stefanos and Pateva, Irina and Teitelbaum, Max and Zong, Zili and Li, Yimei and Jeng, Michael R},
  title = {Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  volume = {71},
  number = {3},
  doi = {10.1002/pbc.30779}
}
Kostenlos starten →